Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bipolar Disorder01:30

Bipolar Disorder

1.4K
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
1.4K
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

771
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
771
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

662
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
662
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

1.2K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.2K
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

1.1K
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Qualitative Experience with an Adherence Promotion Intervention Among Individuals with Bipolar Disorder: What Is Helpful and Unhelpful?

Medicina (Kaunas, Lithuania)·2026
Same author

Geographic Disparities in People with Epilepsy: Differences in Self-Efficacy and Quality of Life.

Journal of epilepsy research·2026
Same author

Depression and associated factors among primary school adolescents with hearing impairment in Kampala district, Uganda: A cross-sectional study.

PLOS mental health·2026
Same author

The TargetEd MAnageMent Intervention for Reducing Stroke Risk in Black Men: A 6-Month Prospective Randomized Controlled Trial.

International journal of aging & human development·2026
Same author

Clinical and Sociodemographic Correlates of Poor Medication Adherence in People With Bipolar Disorder: A Systematic Review and Meta-Analysis.

Bipolar disorders·2026
Same author

Outcomes of Cardiovascular Surgery in Patients With Multiple Sclerosis.

JAMA surgery·2026

Related Experiment Video

Updated: Mar 28, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.7K

Asenapine for bipolar disorder.

Thomas Scheidemantel1, Irina Korobkova2, Soham Rej3

  • 1University Hospitals Case Medical Center, Cleveland, OH, USA.

Neuropsychiatric Disease and Treatment
|December 18, 2015
PubMed
Summary

Asenapine is an effective atypical antipsychotic for acute manic episodes in bipolar disorder (BD), showing comparable results to olanzapine. While generally well-tolerated, further research is needed for depressive symptoms and long-term BD treatment.

Keywords:
asenapinebipolardepressive featuresmanic episodemixed episodesafetytolerability

More Related Videos

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.6K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.7K

Related Experiment Videos

Last Updated: Mar 28, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.7K
Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.6K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.7K

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Asenapine is an atypical antipsychotic approved for schizophrenia and acute manic/mixed episodes of bipolar disorder (BD).
  • It possesses unique sublingual administration and antidopaminergic/antiserotonergic properties.

Purpose of the Study:

  • To review and summarize existing literature on the safety, efficacy, and tolerability of asenapine in treating BD.

Main Methods:

  • Review of randomized, double-blind trials comparing asenapine to placebo or olanzapine.
  • Analysis of data on adverse effects, efficacy in manic/mixed episodes, and limited data on depressive symptoms and maintenance treatment.

Main Results:

  • Asenapine demonstrated efficacy in acute manic/mixed episodes, outperforming placebo and showing noninferiority to olanzapine.
  • Somnolence was the most common adverse effect but rarely led to discontinuation.
  • Modest weight gain, modest impact on glycemic/lipid levels, and no significant QTc prolongation were observed.
  • Akathisia was the most frequent extra-pyramidal symptom.

Conclusions:

  • Asenapine is an effective and relatively well-tolerated treatment for acute manic and mixed episodes of BD.
  • More robust data are required for its use in depressive symptoms and the maintenance phase of BD.